Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Emory researchers are the first to show unprecedented control of SIV replication and decay of viral reservoirs by combining a ...

Researchers have shown unprecedented control of SIV replication and decay of viral reservoirs by combining a stringent model of infection with the interruption of antiretroviral therapy (ART). The ...

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Radiant Biotherapeutics, whose labs are located in Toronto, aims to use the financing to pursue its signature technology, an ...

a cell-surface receptor that is exploited by HIV to bind to cells before viral entry. Merck's raltegravir inhibits HIV integrase, an enzyme that integrates the viral DNA into the DNA of the host cell.

In a sneak peek of his panel discussion at this Thursday’s AI Deciphered summit, Merck’s digital privacy director ... and ViiV’s recent activation around HIV awareness in the South.

Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care ...

Likewise, if you think about immunology and TL1A, I mean, just right there, that's three, and we also have our own internal in HIV. So just those four therapeutic areas providing diversification ...